Association of serum interleukin‑10, interleukin‑17A and transforming growth factor‑α levels with human benign and malignant breast diseases

Lv,Zhuangwei; Liu,Min; Shen,Jinghui; Xiang,Dong; Ma,Yunfeng; Ji,Yanhong

doi:10.3892/etm.2018.6109

Association of serum interleukin‑10, interleukin‑17A and transforming growth factor‑α levels with human benign and malignant breast diseases

Authors:
- Zhuangwei Lv
- Min Liu
- Jinghui Shen
- Dong Xiang
- Yunfeng Ma
- Yanhong Ji
View Affiliations

Affiliations: Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China, Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Division of Hematology and Oncology, St. Louis University, St. Louis, MO 63103, USA
Published online on: April 30, 2018 https://doi.org/10.3892/etm.2018.6109
Pages: 5475-5480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑10 (IL‑10), interleukin‑17A (IL‑17A) and transforming growth factor α (TGF‑α) have been implicated in the progression of breast cancer. However, the diagnostic and prognostic roles of these cytokines in ductal carcinoma remain unclear. The present study therefore aimed to determine the serum levels of IL‑10, IL‑17 and TGF‑α in subjects with benign and malignant breast diseases and to evaluate the clinical significance of these cytokines in ductal carcinoma. Pre‑operative serum samples were collected from 378 patients with breast disease and 70 healthy subjects. IL‑10, IL‑17A and TGF‑α levels were measured using ELISA. Serum levels of these cytokine in patients with different breast diseases were evaluated. Furthermore, correlations between levels of these cytokines and the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in ductal carcinoma were determined. The results demonstrated that serum levels of IL‑10 and IL‑17A were significantly increased in subjects with atypical hyperplasia and ductal carcinoma. Furthermore, IL‑10 and IL‑17A levels were increased in patients with a more serious clinical tumor stage and tumors that were ER‑ and PR‑. Furthermore, high serum levels of TGF‑α were associated with HER2+ tumors. A strong positive correlation was identified between TGF‑α and IL‑17A levels. Therefore, the results of the current study revealed that elevated serum IL‑10, IL‑17A and TGF‑α levels are strongly associated with ductal carcinoma, specifically with tumor stage. High serum levels of IL‑10 and IL‑17A were also associated with the negative expression of ER and PR in ductal carcinoma, and high serum levels of TGF‑α were associated with the positive expression of HER2 in ductal carcinoma. Thus, serum cytokine levels may be measured to identify patients with a poor prognosis who may benefit from more aggressive management and treatment.

View Figures

View References

1	Amin AL, Purdy AC, Mattingly JD, Kong AL and Termuhlen PM: Benign breast disease. Surg Clin North Am. 93:299–308. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jiang X and Shapiro DJ: The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 382:673–682. 2014. View Article : Google Scholar : PubMed/NCBI
3	McEvoy MP, Coopey SB, Mazzola E, Buckley J, Belli A, Polubriaginof F, Merrill AL, Tang R, Garber JE, Smith BL, et al: Breast cancer risk and follow-up recommendations for young women diagnosed with atypical hyperplasia and Lobular Carcinoma In Situ (LCIS). Ann Surg Oncol. 22:3346–3349. 2015. View Article : Google Scholar : PubMed/NCBI
4	Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, Martzen M and Torkelson C: Breast cancer and the immune system. J Soc Integr Oncol. 6:158–168. 2008.PubMed/NCBI
5	DeNardo DG and Coussens LM: Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9:2122007. View Article : Google Scholar : PubMed/NCBI
6	Robertson FM, Ross MS, Tober KL, Long BW and Oberyszyn TM: Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. Carcinogenesis. 17:1719–1728. 1996. View Article : Google Scholar : PubMed/NCBI
7	Schmid BC, Rudas M, Rezniczek GA, Leodolter S and Zeillinger R: CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat. 84:247–250. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chin AR and Wang SE: Cytokines driving breast cancer stemness. Mol Cell Endocrinol. 382:598–602. 2014. View Article : Google Scholar : PubMed/NCBI
9	Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, et al: IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 3:34562013. View Article : Google Scholar : PubMed/NCBI
10	Booth BW and Smith GH: Roles of transforming growth factor-alpha in mammary development and disease. Growth Factors. 25:227–235. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bastid J, Bonnefoy N, Eliaou JF and Bensussan A: Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology. 3:e282732014. View Article : Google Scholar : PubMed/NCBI
12	Chen WC, Lai YH, Chen HY, Guo HR, Su IJ and Chen HH: Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 63:225–233. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kornasiewicz O, Grąt M, Dudek K, Lewandowski Z, Gorski Z, Zieniewicz K and Krawczyk M: Serum levels of HGF, IL-6, and TGF-α after benign liver tumor resection. Adv Med Sci. 60:173–177. 2015. View Article : Google Scholar : PubMed/NCBI
14	Hamidullah, Changkija B and Konwar R: Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 133:11–21. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mittal SK and Roche PA: Suppression of antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015. View Article : Google Scholar : PubMed/NCBI
16	Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, Eko FO, Lyn D and Black CM: Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: Potential for cellular vaccine development. J Immunol. 164:4212–4219. 2000. View Article : Google Scholar : PubMed/NCBI
17	Kozlowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.PubMed/NCBI
18	Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI and Morales-Montor J: The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 35:1–16. 2015. View Article : Google Scholar : PubMed/NCBI
19	Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H and Tatebe S: Serum interleukin-6 and −10 levels in patients with gastric cancer. Gastric Cancer. 12:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
20	Goldberg JE and Schwertfeger KL: Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 11:1133–1146. 2010. View Article : Google Scholar : PubMed/NCBI
21	Jarnicki AG, Lysaght J, Todryk S and Mills KH: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 177:896–904. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhang HZ, Li XH, Zhang X, Zhang ZY, Meng YL, Xu SW, Zheng Y, Zhu ZL, Cui DS, Huang LX, et al: PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma. Chemotherapy. 56:291–297. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G: Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI
24	Suzuki M, Matsushima-Nishiwaki R, Kuroyanagi G, Suzuki N, Takamatsu R, Furui T, Yoshimi N, Kozawa O and Morishige K: Regulation by heat shock protein 22 (HSPB8) of transforming growth factor-α-induced ovary cancer cell migration. Arch Biochem Biophys. 571:40–49. 2015. View Article : Google Scholar : PubMed/NCBI